ArticleBlood research2020

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.

Maria Gemelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.